Tyrosine kinase inhibitorFDA-approvedFirst-line
Squibb's Tarceva
Generic name: erlotinib
How it works
Blocks the epidermal growth factor receptor (EGFR) on cancer cells, preventing them from growing and dividing.
Cancer types
Lung Cancer— EGFR-mutated
Efficacy
In clinical trials, around 50% of EGFR-mutated patients achieved an objective response, with median progression-free survival of approximately 13.8 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Erlotinib Resistance in Lung Cancer: New Insights | Lung Cancer | lab-study | — | Source → |
| Zebrafish Study Identifies Erlotinib as Potential Wnt Inhibitor for Leukemia | Leukemia | lab-study | Erlotinib treatment reduced self-renewal in human T-cell Acute Lymphoblastic Leukemia cells. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.